Overview

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Adalimumab
Methotrexate